Vibegron CAS# 1190389-15-1 维贝格龙
Vibegron, also known as MK-4618, is a potent and selective Beta 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder (OAB). Vibegron has no unacceptable toxicity in preclinical species. Vibegron is currently in Phase 3 human clinical trials for the treatment of OAB. β3-adrenergic receptor (β3-AR) agonists were investigated as potential treatments for obesity and/or diabetes owing to their ability to induce lipolysis, thermogenesis, and antihyperglycemic activity in preclinical species.
📌 参考资料/链接：
Highly diastereoselective total synthesis of Vibegron, a drug for overactive bladder diseaseBy: Adarsh, D. R.; et alTetrahedron Letters (2025), 155, 155429
Highly diastereoselective total synthesis of Vibegron, a drug for overactive bladder diseaseBy: Adarsh, D. R.; et alTetrahedron Letters (2025), 155, 155429
📄 详细内容
CAS No. 1190389-15-1 维贝格龙Vibegron synthetic routes
Highly diastereoselective total synthesis of Vibegron, a drug for overactive bladder diseaseBy: Adarsh, D. R.; et alTetrahedron Letters (2025), 155, 155429
产品链接: CAS No. 1190389-15-1 ››
Highly diastereoselective total synthesis of Vibegron, a drug for overactive bladder diseaseBy: Adarsh, D. R.; et alTetrahedron Letters (2025), 155, 155429
产品链接: CAS No. 1190389-15-1 ››